Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : Solrikitug
Therapeutic Area : Undisclosed
Study Phase : Phase I
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Undisclosed
Product Name : Undisclosed
Product Type : Antibody
Upfront Cash : Inapplicable
March 10, 2025
Lead Product(s) : Solrikitug
Therapeutic Area : Undisclosed
Highest Development Status : Phase I
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : XW003
Therapeutic Area : Undisclosed
Study Phase : Phase I
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
A Study to Investigate Efficacy and Safety of NSI-8226 in Healthy Participants
Details : Undisclosed
Product Name : Undisclosed
Product Type : Peptide
Upfront Cash : Inapplicable
October 15, 2024
Lead Product(s) : XW003
Therapeutic Area : Undisclosed
Highest Development Status : Phase I
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Solrikitug
Therapeutic Area : Gastroenterology
Study Phase : Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
A Study to Investigate the Efficacy and Safety of NSI-8226 in Adults with Eosinophilic Esophagitis
Details : Undisclosed
Product Name : Undisclosed
Product Type : Antibody
Upfront Cash : Inapplicable
September 19, 2024
Lead Product(s) : Solrikitug
Therapeutic Area : Gastroenterology
Highest Development Status : Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Solrikitug
Therapeutic Area : Pulmonary/Respiratory Diseases
Study Phase : Phase II
Sponsor : DevPro Biopharma
Deal Size : Inapplicable
Deal Type : Inapplicable
A Study to Evaluate Solrikitug in Participants With COPD (ZION)
Details : Undisclosed
Product Name : Undisclosed
Product Type : Antibody
Upfront Cash : Inapplicable
July 11, 2024
Lead Product(s) : Solrikitug
Therapeutic Area : Pulmonary/Respiratory Diseases
Highest Development Status : Phase II
Sponsor : DevPro Biopharma
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : NSI-8226
Therapeutic Area : Pulmonary/Respiratory Diseases
Study Phase : Phase II
Sponsor : DevPro Biopharma
Deal Size : Inapplicable
Deal Type : Inapplicable
A Study to Evaluate Solriktug in Adult Participants With Asthma
Details : Undisclosed
Product Name : Undisclosed
Product Type : Undisclosed
Upfront Cash : Inapplicable
July 11, 2024
Lead Product(s) : NSI-8226
Therapeutic Area : Pulmonary/Respiratory Diseases
Highest Development Status : Phase II
Sponsor : DevPro Biopharma
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Solrikitug
Therapeutic Area : Pulmonary/Respiratory Diseases
Study Phase : Phase I
Sponsor : Blackstone Life Sciences
Deal Size : Inapplicable
Deal Type : Inapplicable
Blackstone Launches Uniquity Bio For Novel Immunology And Inflammation Medicines
Details : MK-8226 (solrikitug), is a highly potent anti-TSLP monoclonal antibody, which is being evaluated in early-stage clinical trial for the treatment of chronic obstructive pulmonary disease and asthma.
Product Name : Undisclosed
Product Type : Antibody
Upfront Cash : Inapplicable
May 15, 2024
Lead Product(s) : Solrikitug
Therapeutic Area : Pulmonary/Respiratory Diseases
Highest Development Status : Phase I
Sponsor : Blackstone Life Sciences
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Solrikitug
Therapeutic Area : Pulmonary/Respiratory Diseases
Study Phase : Phase I
Sponsor : Blackstone Life Sciences
Deal Size : $300.0 million
Deal Type : Financing
Blackstone Unsheathes Uniquity Bio with $300M
Details : The financing aims to fund the clinical development of MK-8226 (solrikitug), which is being evaluated in the early-stage clinical trial for chronic obstructive pulmonary disease and asthma.
Product Name : Undisclosed
Product Type : Antibody
Upfront Cash : Undisclosed
May 15, 2024
Lead Product(s) : Solrikitug
Therapeutic Area : Pulmonary/Respiratory Diseases
Highest Development Status : Phase I
Sponsor : Blackstone Life Sciences
Deal Size : $300.0 million
Deal Type : Financing